260 related articles for article (PubMed ID: 22492545)
1. Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients.
Slaby O; Redova M; Poprach A; Nekvindova J; Iliev R; Radova L; Lakomy R; Svoboda M; Vyzula R
Genes Chromosomes Cancer; 2012 Jul; 51(7):707-16. PubMed ID: 22492545
[TBL] [Abstract][Full Text] [Related]
2. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma.
Redova M; Poprach A; Nekvindova J; Iliev R; Radova L; Lakomy R; Svoboda M; Vyzula R; Slaby O
J Transl Med; 2012 Mar; 10():55. PubMed ID: 22440013
[TBL] [Abstract][Full Text] [Related]
3. Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy.
Slaby O; Jancovicova J; Lakomy R; Svoboda M; Poprach A; Fabian P; Kren L; Michalek J; Vyzula R
J Exp Clin Cancer Res; 2010 Jul; 29(1):90. PubMed ID: 20609231
[TBL] [Abstract][Full Text] [Related]
4. Molecular Characterization of Renal Cell Carcinoma: A Potential Three-MicroRNA Prognostic Signature.
Lokeshwar SD; Talukder A; Yates TJ; Hennig MJP; Garcia-Roig M; Lahorewala SS; Mullani NN; Klaassen Z; Kava BR; Manoharan M; Soloway MS; Lokeshwar VB
Cancer Epidemiol Biomarkers Prev; 2018 Apr; 27(4):464-472. PubMed ID: 29440068
[No Abstract] [Full Text] [Related]
5. MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma.
Mytsyk Y; Borys Y; Tumanovska L; Stroy D; Kucher A; Gazdikova K; Rodrigo L; Kruzliak P; Prosecky R; Urdzik P; Dosenko V
Clin Exp Med; 2019 Nov; 19(4):515-524. PubMed ID: 31440867
[TBL] [Abstract][Full Text] [Related]
6. Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma.
Heinemann FG; Tolkach Y; Deng M; Schmidt D; Perner S; Kristiansen G; Müller SC; Ellinger J
Clin Epigenetics; 2018; 10():11. PubMed ID: 29410711
[TBL] [Abstract][Full Text] [Related]
7. The miR-200 family as prognostic markers in clear cell renal cell carcinoma.
Saleeb R; Kim SS; Ding Q; Scorilas A; Lin S; Khella HW; Boulos C; Ibrahim G; Yousef GM
Urol Oncol; 2019 Dec; 37(12):955-963. PubMed ID: 31635993
[TBL] [Abstract][Full Text] [Related]
8. MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma.
Redova M; Poprach A; Besse A; Iliev R; Nekvindova J; Lakomy R; Radova L; Svoboda M; Dolezel J; Vyzula R; Slaby O
Tumour Biol; 2013 Feb; 34(1):481-91. PubMed ID: 23150176
[TBL] [Abstract][Full Text] [Related]
9. The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma.
Fritz HKM; Lindgren D; Ljungberg B; Axelson H; Dahlbäck B
Eur J Cancer; 2014 Jul; 50(10):1758-1765. PubMed ID: 24793999
[TBL] [Abstract][Full Text] [Related]
10. Global and Targeted miRNA Expression Profiling in Clear Cell Renal Cell Carcinoma Tissues Potentially Links miR-155-5p and miR-210-3p to both Tumorigenesis and Recurrence.
Zhang J; Ye Y; Chang DW; Lin SH; Huang M; Tannir NM; Matin S; Karam JA; Wood CG; Chen ZN; Wu X
Am J Pathol; 2018 Nov; 188(11):2487-2496. PubMed ID: 30201497
[TBL] [Abstract][Full Text] [Related]
11. 4-miRNA Score Predicts the Individual Metastatic Risk of Renal Cell Carcinoma Patients.
Heinzelmann J; Arndt M; Pleyers R; Fehlmann T; Hoelters S; Zeuschner P; Vogt A; Pryalukhin A; Schaeffeler E; Bohle RM; Gajda M; Janssen M; Stoeckle M; Junker K
Ann Surg Oncol; 2019 Oct; 26(11):3765-3773. PubMed ID: 31270716
[TBL] [Abstract][Full Text] [Related]
12. Potential prognostic value of miRNAs as biomarker for progression and recurrence after nephrectomy in renal cell carcinoma: a literature review.
Fasanella D; Antonaci A; Esperto F; Scarpa RM; Ferro M; Schips L; Marchioni M
Diagnosis (Berl); 2021 Oct; 9(2):157-165. PubMed ID: 34674417
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of meta-signature miRNAs in renal cell carcinoma: an integrated miRNA expression profiling analysis.
Tang K; Xu H
Sci Rep; 2015 May; 5():10272. PubMed ID: 25974855
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of miR-183-5p predicts worse survival in patients with renal cell cancer after surgery.
Li H; Pan X; Gui Y; Quan J; Li Z; Zhao L; Guan X; Xu J; Xu W; Lai Y
Cancer Biomark; 2019; 24(2):153-158. PubMed ID: 30689558
[TBL] [Abstract][Full Text] [Related]
15. Combination of expression levels of miR-21 and miR-126 is associated with cancer-specific survival in clear-cell renal cell carcinoma.
Vergho D; Kneitz S; Rosenwald A; Scherer C; Spahn M; Burger M; Riedmiller H; Kneitz B
BMC Cancer; 2014 Jan; 14():25. PubMed ID: 24428907
[TBL] [Abstract][Full Text] [Related]
16. miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215.
White NM; Khella HW; Grigull J; Adzovic S; Youssef YM; Honey RJ; Stewart R; Pace KT; Bjarnason GA; Jewett MA; Evans AJ; Gabril M; Yousef GM
Br J Cancer; 2011 Nov; 105(11):1741-9. PubMed ID: 22033272
[TBL] [Abstract][Full Text] [Related]
17. CREB1 is affected by the microRNAs miR-22-3p, miR-26a-5p, miR-27a-3p, and miR-221-3p and correlates with adverse clinicopathological features in renal cell carcinoma.
Friedrich M; Heimer N; Stoehr C; Steven A; Wach S; Taubert H; Hartmann A; Seliger B
Sci Rep; 2020 Apr; 10(1):6499. PubMed ID: 32300145
[TBL] [Abstract][Full Text] [Related]
18. miR-129-3p, as a diagnostic and prognostic biomarker for renal cell carcinoma, attenuates cell migration and invasion via downregulating multiple metastasis-related genes.
Chen X; Ruan A; Wang X; Han W; Wang R; Lou N; Ruan H; Qiu B; Yang H; Zhang X
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1295-304. PubMed ID: 24802708
[TBL] [Abstract][Full Text] [Related]
19. Functional analysis of serum microRNAs miR-21 and miR-106a in renal cell carcinoma.
Tusong H; Maolakuerban N; Guan J; Rexiati M; Wang WG; Azhati B; Nuerrula Y; Wang YJ
Cancer Biomark; 2017; 18(1):79-85. PubMed ID: 27814278
[TBL] [Abstract][Full Text] [Related]
20. miR-566 functions as an oncogene and a potential biomarker for prognosis in renal cell carcinoma.
Pan X; Quan J; Li Z; Zhao L; Zhou L; Jinling X; Weijie X; Guan X; Li H; Yang S; Gui Y; Lai Y
Biomed Pharmacother; 2018 Jun; 102():718-727. PubMed ID: 29604591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
